These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 35226081)

  • 21. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    Al-Batran SE; Homann N; Pauligk C; Illerhaus G; Martens UM; Stoehlmacher J; Schmalenberg H; Luley KB; Prasnikar N; Egger M; Probst S; Messmann H; Moehler M; Fischbach W; Hartmann JT; Mayer F; Höffkes HG; Koenigsmann M; Arnold D; Kraus TW; Grimm K; Berkhoff S; Post S; Jäger E; Bechstein W; Ronellenfitsch U; Mönig S; Hofheinz RD
    JAMA Oncol; 2017 Sep; 3(9):1237-1244. PubMed ID: 28448662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
    Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
    Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.
    Zang M; Hu X; Yuan G; Li R; Li W; Pang H; Li Q; Chen J
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111019. PubMed ID: 37879230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.
    Yamada Y; Higuchi K; Nishikawa K; Gotoh M; Fuse N; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
    Ann Oncol; 2015 Jan; 26(1):141-148. PubMed ID: 25316259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
    Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
    JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
    Tsuji K; Yasui H; Onozawa Y; Boku N; Doyama H; Fukutomi A; Yamazaki K; Machida N; Todaka A; Taniguchi H; Tsushima T; Yokota T
    Jpn J Clin Oncol; 2012 Aug; 42(8):686-90. PubMed ID: 22693245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.
    Catenacci DVT; Chase L; Lomnicki S; Karrison T; de Wilton Marsh R; Rampurwala MM; Narula S; Alpert L; Setia N; Xiao SY; Hart J; Siddiqui UD; Peterson B; Moore K; Kipping-Johnson K; Markevicius U; Gordon B; Allen K; Racette C; Maron SB; Liao CY; Polite BN; Kindler HL; Turaga K; Prachand VN; Roggin KK; Ferguson MK; Posner MC
    JAMA Netw Open; 2020 Feb; 3(2):e1921290. PubMed ID: 32058557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
    Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
    Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
    Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
    JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative Treatment of Locally Advanced Rectal Cancer.
    Schrag D; Shi Q; Weiser MR; Gollub MJ; Saltz LB; Musher BL; Goldberg J; Al Baghdadi T; Goodman KA; McWilliams RR; Farma JM; George TJ; Kennecke HF; Shergill A; Montemurro M; Nelson GD; Colgrove B; Gordon V; Venook AP; O'Reilly EM; Meyerhardt JA; Dueck AC; Basch E; Chang GJ; Mamon HJ
    N Engl J Med; 2023 Jul; 389(4):322-334. PubMed ID: 37272534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
    Park H; Jin RU; Wang-Gillam A; Suresh R; Rigden C; Amin M; Tan BR; Pedersen KS; Lim KH; Trikalinos NA; Acharya A; Copsey ML; Navo KA; Morton AE; Gao F; Lockhart AC
    JAMA Oncol; 2020 Aug; 6(8):1231-1240. PubMed ID: 32469386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.
    Hofheinz RD; Hegewisch-Becker S; Kunzmann V; Thuss-Patience P; Fuchs M; Homann N; Graeven U; Schulte N; Merx K; Pohl M; Held S; Keller R; Tannapfel A; Al-Batran SE
    Int J Cancer; 2021 Sep; 149(6):1322-1331. PubMed ID: 34019698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.
    Kang YK; Chin K; Chung HC; Kadowaki S; Oh SC; Nakayama N; Lee KW; Hara H; Chung IJ; Tsuda M; Park SH; Hosaka H; Hironaka S; Miyata Y; Ryu MH; Baba H; Hyodo I; Bang YJ; Boku N
    Lancet Oncol; 2020 Aug; 21(8):1045-1056. PubMed ID: 32682457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 37. Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial.
    Li N; Zhu Y; Liu LY; Feng YR; Wang WL; Wang J; Wang H; Li GF; Tang Y; Hu C; Liu WY; Ren H; Wang SL; Wang WH; Song YW; Liu YP; Fang H; Tang Y; Lu NN; Chen B; Qi SN; Liu XF; Li YX; Jin J
    JAMA Netw Open; 2021 Nov; 4(11):e2136116. PubMed ID: 34846525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial.
    Zhao Q; Lian C; Huo Z; Li M; Liu Y; Fan L; Tan B; Zhao X; Zhang Z; Wang D; Liu Y; Guo H; Yang P; Tian Y; Li Y
    Cancer Med; 2020 Aug; 9(16):5731-5745. PubMed ID: 32583567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma.
    Lim SH; Shim YM; Park SH; Kim HK; Choi YS; Ahn MJ; Park K; Zo JI; Sun JM
    Cancer Res Treat; 2017 Jul; 49(3):816-823. PubMed ID: 27857024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
    Conroy T; Galais MP; Raoul JL; Bouché O; Gourgou-Bourgade S; Douillard JY; Etienne PL; Boige V; Martel-Lafay I; Michel P; Llacer-Moscardo C; François E; Créhange G; Abdelghani MB; Juzyna B; Bedenne L; Adenis A;
    Lancet Oncol; 2014 Mar; 15(3):305-14. PubMed ID: 24556041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.